# Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

Study · id `cardio:ct-nct01659580` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01659580](<https://clinicaltrials.gov/study/NCT01659580>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT01659580

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1004 participants.

## Technical summary

Registry record NCT01659580. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1004 participants (enrolled count; ClinicalTrials.gov record NCT01659580, source copy `cardio:ctgov-nct01659580-2017-03-09`, retrieved 2026-11-18)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01659580, source copy `cardio:ctgov-nct01659580-2017-03-09`, retrieved 2026-11-18)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT01659580, source copy `cardio:ctgov-nct01659580-2017-03-09`, retrieved 2026-11-18)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT01659580, source copy `cardio:ctgov-nct01659580-2017-03-09`, retrieved 2026-11-18)
- Countries: United States; Belarus; Canada; Georgia; Mexico; Russia; Ukraine (ClinicalTrials.gov record NCT01659580, source copy `cardio:ctgov-nct01659580-2017-03-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01659580-2017-03-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
- Acronym: CAESA
- Condition: Angina Pectoris
- Intervention (Drug): T89 high dose
- Intervention (Drug): T89 Low dose
- Intervention (Drug): Sanqi+Bingpian
- Intervention (Drug): Placebo
- Lead sponsor: Tasly Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)

## Provenance

Content hash: d56af27b0c5fe9839fbd44e38535f5a5d05a460ae8c5d6526f9fa84ebaeb08b8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
